In independent interviews with Real Endpoints analysts, Aetna, UnitedHealth, GSK and others discuss the 7 key issues that will set the reimbursement agenda for the next 24 months ‚Äď and beyond.
Online PR News – 03-October-2012 – Westport, CT – Product reimbursement sits at the epicenter of the healthcare payment revolution. Product payments are 50%-plus of most plans‚Äô controllable costs. And they‚Äôre everything to pharma and med-device businesses.
‚Ä¶ from radical new payment mechanisms‚Ä¶
‚Ä¶ to risk-sharing‚Ä¶
‚Ä¶ to real-world evidence requirements‚Ä¶
‚Ä¶ to innovations in adherence and other patient management programs‚Ä¶
‚Ä¶ product reimbursement has never been more challenging, the pace of change faster, the stakes higher.
The Real Endpoints team and some of the top thought leaders in product reimbursement focus on substantive analysis and actionable answers to the practical problems payers and product companies have in valuing, contracting for and implementing innovation.
In these interviews‚Ä¶
‚ÄúWhat Payers Want: An Interview with GSK‚Äôs Jack Bailey‚ÄĚ http://realendpoints.com/2012/10/what-payers-want-an-interview-with-gsks-jack-bailey/
Jack Bailey, the man in charge of GlaxoSmithKline‚Äôs US goverment affairs, public policy and payer marketing business unit, knows his company has to change. As providers and payers move from the incentives of a fee-for-service model to one that focuses on value, and are exploring new approaches such as risk-sharing and bundled payments, drug firms like GSK need to make sure that a ‚Äúnew medicine [has] a compelling value proposition, particularly for payers,‚ÄĚ said Bailey. ‚Ä¶
"Zeke Emanuel: Re-Incentivizing Pharma & Device Companies to Solve Technology‚Äôs Data Problem" http://realendpoints.com/2012/09/zeke-emanuel-re-incentivizing-pharma-device-companies-to-solve-technologys-data-problem/
Zeke Emanuel would like to set the record straight. He‚Äôs not against new medical technology. Indeed, the UPenn med school and Wharton professor calls the profusion of industry-generated new technologies ‚Äúa great thing‚ÄĚ. But his support is necessarily tempered ‚ÄĒ a wariness born from his days as a health policy advisor in the Clinton and Obama administrations. Emanuel‚Äôs willingness to critique newer, costlier innovations that deliver results no better than older, cheaper technologies has ‚Ä¶
"The Requisite Data: A Discussion with United‚Äôs Lew Sandy" http://realendpoints.com/2012/09/the-requisite-data-a-discussion-with-uniteds-lew-sandy/
What goes around comes around. ‚ÄúEmployers are asking: what proportion of your reimbursement [spending] on physicians, hospitals‚Ä¶or pharmaceutical companies is performance-based,‚ÄĚ says Lewis Sandy, MD, SVP Clinical Advancement at UnitedHealth and principal in its Center for Reform and Modernization. ‚ÄĚAnd we‚Äôre being scorecarded against that.‚ÄĚ Which means, for product companies, that either risk-sharing is going to be the dominant marketing tool to payers (if your drug achieves ‚Ä¶
"Managing Molecular Diagnostics: The View from Aetna‚Äôs Ira Klein" http://realendpoints.com/2012/09/managing-molecular-diagnostics-what-one-payer-thinks/
What could be more intuitive than providing the right medicine to the right patient at the right time? Alas, the actual implementation of personalized medicine is frustratingly imprecise‚ÄĒand, increasingly, expensive. And that‚Äôs a big concern for payers who wrestle with questions of cost, and what constitutes clinical validation and utility when making diagnostic coverage decisions. Not only is it a topic of discussion at our inaugural Real Endpoints Symposium (taking place November 1-2 in Philadelphia). ‚Ä¶
Read and hear more what these thought leaders have to say at http://realendpoints.com/symposium/pre-symposium-podcasts/